Mdm2 inhibits the function of the p53 tumor suppressor. Mdm2 is overexpressed in many tumors with wild-type p53 suggesting an alternate mechanism of loss of p53 activity in tumors. An Mdm2-binding protein (MTBP) was identified using a yeast two-hybrid screen. In tissue culture, MTBP inhibits Mdm2 self-ubiquitination, leading to stabilization of Mdm2 and increased degradation of p53. To address the role of MTBP in the regulation of the p53 pathway in vivo, we deleted the Mtbp gene in mice. Homozygous disruption of Mtbp resulted in early embryonic lethality, which was not rescued by loss of p53. Mtbp þ /À mice were not tumor prone. When mice were sensitized for tumor development by p53 heterozygosity, we found that the Mtbp þ /À p53 Introduction p53 is a transcription factor that activates numerous downstream genes with roles in cell cycle arrest, apoptosis, DNA repair and senescence (Levine et al., 2004) . As such, disruption of the p53 pathway is a critical event in human cancer. Mutations or deletions in the p53 gene occur in approximately 50% of cancers (Bartek et al., 1991; Levine, 1993; Vogelstein et al., 2000) . The p53 pathway is also inactivated by overexpression of the p53 inhibitor, Mdm2. Overexpression of Mdm2 by several mechanisms occurs in about 30% of sarcomas and many other types of tumors (Iwakuma and Lozano, 2003) . ARF (alternative reading frame of the Ink 4a locus), another important regulator of this pathway, binds and inhibits Mdm2 by relocating Mdm2 from nucleus to nucleolus (Sharpless and DePinho, 1999; Weber et al., 1999) . Therefore, ARF loss in tumors releases Mdm2, leading to increased binding to and inactivation of p53. Thus, the ARF-Mdm2-p53 pathway is a key pathway that must be bypassed in tumor development.
Introduction
p53 is a transcription factor that activates numerous downstream genes with roles in cell cycle arrest, apoptosis, DNA repair and senescence (Levine et al., 2004) . As such, disruption of the p53 pathway is a critical event in human cancer. Mutations or deletions in the p53 gene occur in approximately 50% of cancers (Bartek et al., 1991; Levine, 1993; Vogelstein et al., 2000) . The p53 pathway is also inactivated by overexpression of the p53 inhibitor, Mdm2. Overexpression of Mdm2 by several mechanisms occurs in about 30% of sarcomas and many other types of tumors (Iwakuma and Lozano, 2003) . ARF (alternative reading frame of the Ink 4a locus), another important regulator of this pathway, binds and inhibits Mdm2 by relocating Mdm2 from nucleus to nucleolus (Sharpless and DePinho, 1999; Weber et al., 1999) . Therefore, ARF loss in tumors releases Mdm2, leading to increased binding to and inactivation of p53. Thus, the ARF-Mdm2-p53 pathway is a key pathway that must be bypassed in tumor development.
Experiments using genetically engineered mice have provided direct evidence for the importance of these factors in tumorigenesis. Mice with homozygous or heterozygous deletion of p53 develop tumors (Donehower et al., 1992; Tsukada et al., 1993; Jacks et al., 1994; Purdie et al., 1994) . Mice with missense mutations identical to those found in humans with Li-Fraumeni syndrome develop a variety of tumors with frequent metastasis (Lang et al., 2004; Olive et al., 2004) . Further, mutant p53 heterozygous mice develop more aggressive tumors compared to p53 þ /À mice, suggesting that missense mutations have gain-of-function activities.
Experiments in mice defined the role of Mdm2 as an important p53 inhibitor. Mdm2-null mice show embryonic lethality that is completely rescued by a concomitant deletion of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995) . With regard to tumorigenesis, decreased Mdm2 gene dosage inhibited cMyc-induced lymphomagenesis, and intestinal adenoma formation in Apc min þ /À mice (Alt et al., 2003; Mendrysa et al., 2006) . Transgenic mice that overexpress Mdm2 are also tumor prone establishing a causal role of Mdm2 in tumorigenesis (Lundgren et al., 1997; Jones et al., 1998) . Likewise, a polymorphism in the human MDM2 gene increases MDM2 expression, thus decreasing p53 activity, and leading to an increased risk of tumorigenesis (Bond et al., 2004) . On the other hand, a protein that inhibits Mdm2 can function as a tumor suppressor by activating p53. Mice null for Arf also develop spontaneous tumorigenesis similar to p53-null mice (Kamijo et al., 1997) . Thus, modulation of Mdm2 levels greatly affects p53 activity and tumorigenesis.
MTBP was isolated as a novel Mdm2-binding protein (Boyd et al., 2000) . The MTBP-Mdm2 interaction was observed using purified proteins in vitro and by overexpression in cells. Overexpression of MTBP protects Mdm2 from self-ubiquitination, leading to Mdm2 stabilization and p53 degradation (Brady et al., 2005) . We therefore hypothesized that MTBP affects tumor development through modulation of p53 activity. To test this hypothesis and examine the in vivo physiological function of MTBP, we generated mice with disruption of the Mtbp gene. Our results show that Mtbp-null mice were embryonic lethal, and this phenotype was p53 independent. Mtbp þ /À mice were normal, but when crossed with p53 þ /À mice, Mtbp
þ /À mice developed significantly more metastatic tumors compared to p53 þ /À mice. In vitro invasion assays clearly supported the in vivo results. Thus, our results support a role of MTBP as a metastasis suppressor.
Results

Generation of mice with disruption of Mtbp
Mice with deletion of the ATG and first 14 amino acids of MTBP (encoded by exon 1) were generated ( Figure 1a ). Southern blotting using 5 0 and 3 0 probes outside the region of homology of the targeting vector showed homologous recombination at the Mtbp locus ( Figure 1b . To examine the timing of lethality of Mtbp À/À mice, pregnant female mice were dissected beginning at E9.5 and then backward in time to the blastocyst stage at E3.5. Mtbp À/À embryos were detected only at E3.5 ( Figure 1e ) but not at E7.5 by PCR, suggesting that homozygous disruption of Mtbp caused early embryonic lethality between E3.5 and E7.5.
Disruption of two known genes whose protein products inhibit p53 activity, Mdm2 and Mdm4, causes embryonic lethality due to increased p53 activity (Jones et al., 1995; Montes de Oca Luna et al., 1995; Parant et al., 2001; Finch et al., 2002; Migliorini et al., 2002) . Since MTBP binds Mdm2 and potentially bolsters Mdm2 activity, we tested whether the Mtbp À/À lethality was p53 dependent by crossing Mtbp
In this cross, 1 of 8 mice should be Mtbp
À/À mice were observed at weaning suggesting that the loss of p53 could not completely rescue the Mtbp À/À lethality (data not shown). To examine if lethality is partially rescued by p53 loss, we genotyped 37 embryos at E8.5 from the same cross (Supplementary Table 1 ). While no Mtbp-null embryos were observed, we found 11 empty deciduae, suggesting a very early embryo lethal phenotype. These data indicate that the Mtbp À/À lethality is not simply due to constitutive p53 activation.
A metastatic tumor phenotype in Mtbp
þ /À mice Since MTBP is thought to impinge on the p53/Mdm2 pathway, we tested whether MTBP functioned as a tumor suppressor by sequestering Mdm2 in much the same way as Arf does. A cohort of Mtbp þ /À mice was examined for spontaneous tumor development ( Figure 2a ). Mtbp þ /À mice developed tumors beginning at 17.5 months of age with approximately 35% of Mtbp þ /À mice developing tumors by 24 months of age. However, control littermates wild type for Mtbp also developed tumors with 30% incidence during the same observation period. The difference between these two groups was not statistically significant (log-rank test, P ¼ 0.375). The tumor spectra were also similar between these two groups. Interestingly, a histiocytic sarcoma from an Mtbp þ /À mouse showed metastasis (Table 2) .
Cooperating genetic defects synergize in animal models to increase tumor incidence (Lozano and Zambetti, 2005) . To examine the tumor phenotype in a background with a predetermined risk of cancer, we crossed Mtbp þ /À mice with p53 heterozygous mice
mice showed a slightly earlier tumor onset, but again this difference was not statistically significant ( Figure 2b ). The overall survival of these two groups was also similar because most mice died of tumors (Supplementary Figure S1) . However, Mtbp
mice developed significantly more metastatic tumors than p53 þ /À mice (18.2 vs 2.6%) (Fisher's exact test, P ¼ 0.033) ( Table 2) . Metastatic lesions were identified by histology at secondary sites such as the lung, lymph node, kidney and liver (Table 3) . A representative liver metastasis from a spinal osteosarcoma of an Mtbp Figure 2c . The pathology of metastatic lesions shows pleomorphic tumor cells with osteoid (bone formation) within the liver (Figure 2c ). These results suggest that decreased Mtbp gene dosage enhances tumor metastasis.
To examine the status of the intact Mtbp and p53 alleles in tumors of double heterozygous mice, we performed a loss-of-heterozygosity (LOH) study. DNA was extracted from the innermost part of the solid tumor to avoid contamination of normal tissues as much as possible. For the Mtbp allele, no LOH was detected in 10 Mtbp þ /À and 10 Mtbp Figure 2d ; data not shown), suggesting that complete loss of Mtbp is not required for tumor development. In general, metastatic lesions were too small for LOH studies. However, we also did not detect Mtbp LOH in an osteosarcoma cell line (BP215M) derived from a liver metastasis (Supplementary Figure S2a) . At the p53 locus, five out of ten tumors (50%) from Mtbp
mice showed LOH, and three out of six tumors from p53 þ /À mice (50%) showed LOH, consistent with previously published data for p53 þ /À mice ( Figure 2d ) (Jacks et al., 1994) . Thus, Mtbp LOH was not observed in any tumor examined, and Mtbp heterozygosity did not affect incidence of LOH at the p53 locus.
Because the Mtbp-null lethality was not rescued by loss of p53, and because Mtbp heterozygosity did not show any obvious effects on p53 activity in tumor development, we hypothesized that p53 activity was not increased in Mtbp þ /À heterozygous cells, in contrast to previously published in vitro data (Brady et al., 2005) . To test this hypothesis, we compared p53 and Mdm2 protein levels in thymocytes between wild-type and Mtbp þ /À mice (Figure 2e ). The levels of both p53 and Mdm2 proteins in Mtbp þ /À thymocytes were similar to those in wild-type cells, regardless of the presence of genotoxic stress such as g-irradiation.
MTBP suppresses cell migration and invasion in vitro The in vivo results suggested that MTBP is a potential metastasis suppressor. To investigate further the role of MTBP in metastasis, we first performed cell migration assays using wild-type or Mtbp þ /À MEFs (Figure 3a) . Consistent with the in vivo results, Mtbp þ /À MEFs migrated significantly more than wild-type MEFs. We also performed invasion assays following downmodulation of Mtbp by an Mtbp-specific siRNA in two different Tumor metastasis in Mtbp haploinsufficient mice T Iwakuma et al osteosarcoma cell lines derived from p53 þ /À mice (P932 and P362), which retain wild-type p53 alleles (Figure 3b and Supplementary Figure S2b) . The Mtbp-specific siRNA successfully downmodulated MTBP protein levels (Figure 3b ). Tumor cells with decreased MTBP showed a significant increase in invasion potential compared to the control siRNA (Figure 3b ). To determine if high MTBP levels could inhibit tumor invasion, two different osteosarcoma cell lines from Mtbp
þ /À mice (BP193 and BP215) were infected with an Mtbp-encoding adenovirus. BP193 cells showed LOH of the wild-type p53 allele, while BP215 cells did not (Supplementary Figure S2b) . High levels of MTBP significantly inhibited the invasion potential of both cell lines as compared to control Gfp-expressing cells (Figure 3c ). These invasion assays were performed using conditions in which manipulation of MTBP levels did not affect cell proliferation (Supplementary Figure S3) , nor cell cycle profiles (Supplementary Figure S4) . These results strongly support the in vivo results that MTBP suppresses tumor metastasis.
Modification of Mtbp exon 1 does not affect MrpL13 expression
A recent search of the NCBI database revealed the presence of an overlapping gene at the Mtbp locus. Part of exon 1 of the mitochondrial ribosomal protein L13 (MrpL13) overlaps Mtbp exon 1 on the opposite strand, and is directed in the opposite orientation. Thus, the Mtbp and MrpL13 genes share sequences (Supplementary Figure S5a ). In bacteria, MrpL13 is involved in translation of mitochondrial proteins. In mammalian cells, MrpL13 was identified as a component of the 55S large subunit of bovine ribosomal proteins from mitochondria (Suzuki et al., 2001) . Because this protein is evolutionally conserved from bacteria to humans, MrpL13 may also be involved in translation Tumor metastasis in Mtbp haploinsufficient mice T Iwakuma et al of mitochondrial proteins in mammalian cells (Koc et al., 2001) . Our targeting strategy alters the sequence of 5 0 untranslated region of MrpL13 gene, but does not disrupt the start codon of MrpL13 (Supplementary Figure S5a) . To address the possibility that MrpL13 gene expression was affected by our targeting strategy, we examined the RNA expression of both Mtbp and MrpL13 by quantitative RT-PCR using blastocysts and MEFs (Supplementary Figure S5b, c) . Because homozygous Mtbp-null embryos were observed at E3.5, we examined RNA expression of MrpL13 and Mtbp using E3.5 blastocysts by quantitative RT-PCR. Three blastocysts showed high expression of Mtbp (wild type), 7 showed low Mtbp (heterozygote) and 3 showed no Mtbp expression (homozygous null). All 13 blastocysts showed similar MrpL13 levels. In Mtbp þ /À MEFs, Mtbp mRNA expression was about half of that in wild-type MEFs, while MrpL13 mRNA expression was identical in both (Supplementary Figure S5c) . MrpL13 protein expression in Mtbp þ /À MEFs and thymocytes was the same as that in wild-type cells (Supplementary Figure S5d; data not shown). Taken together, disruption of Mtbp exon 1 does not affect MrpL13 expression.
Discussion
Our in vivo study revealed that decreased expression of MTBP increases the metastatic potential of tumor cells. Mice doubly heterozygous for Mtbp and p53 developed more metastatic tumors as compared to p53 heterozygous mice. This in vivo result was further supported by in vitro invasion assays, in which altered expression of MTBP clearly affected the invasion potential of mouse tumor cells. These data suggest that MTBP is a metastasis suppressor gene.
Several metastasis suppressor genes such as Kai1, Nm23 and Maspin have been identified. Expression of many of these metastasis suppressors is associated with changes in expression of metastasis-related proteins such as matrix metalloproteinase (MMP)2, MMP9, plasminogen activator and E-cadherin, For example, Kai1 suppresses tumor invasion by MMP9 inactivation (Jee et al., 2006) . Maspin inhibits the activity of plasminogen inhibitor (Sheng et al., 1998) . Nm23 increases expression of E-cadherin, and TIMP1 and decreases expression of MMP2 and vascular endothelial growth factor (Che et al., 2006) . MTBP might also affect the expression of these proteins. Unpublished data indicate that MTBP does not affect expression of MMP2, MMP9 and E-cadherin mRNAs. The mechanisms by which these metastasis suppressors inhibit tumor metastasis remain largely unknown.
The effects of MTBP on the p53 pathway are unclear. One study suggests that overexpression of MTBP causes G 1 arrest of cell cycle independent of p53 (Boyd et al., 2000) . The other reported that MTBP decreases p53 activity via the stabilization of Mdm2 by protecting it from self-ubiquitination (Brady et al., 2005) . Thus, MTBP is downstream of Mdm2 in a p53-independent manner, but is also an upstream regulator of Mdm2, leading to decreased p53 activity. Our in vivo studies failed to demonstrate any effects of MTBP on p53 activity. First, Mtbp-null lethality was not rescued by loss of p53 or overexpression of Mdm2 (CME; unpublished data). Second, Mtbp heterozygosity did not alter tumor onset or spectra in a p53 heterozygous background. In contrast, Mdm2 haploinsufficiency delays tumors onset in a B-cell lymphoma model (Alt et al., 2003) . Additionally, a mouse model expressing 30% of Mdm2 levels delays intestinal adenomas in Apc min þ /À mice (Mendrysa et al., 2006) . These in vivo systems show that modulation of Mdm2 levels by as little as twofold has a significant effect on the tumor phenotype. Thus, it is unlikely that MTBP regulates Mdm2 activity. Third, the frequency of LOH of the wild-type p53 allele in tumors from Mtbp
þ /À mice was identical to that of p53 þ /À mice. Additionally, the increased metastatic potential in Mtbp heterozygous mice is likely p53 independent because both p53 þ /À and p53 À/À mice rarely develop metastatic tumors, and because overexpression of MTBP resulted in decreased invasiveness in cells lacking p53. Possibly, MTBP affects the p53 pathway only when overexpressed as in in vitro transfection systems or cell lines.
The expression status of MTBP in human cancers and the regulation of MTBP expression have not yet been examined. Additional studies regarding MTBP expression in human cancers, especially studies to determine the MTBP expression levels in the metastatic lesions compared to the primary cancers are essential for defining MTBP as a metastasis suppressor.
Materials and methods
Southern blotting
The linearized vector was electroporated into 129SV/Ev/AB1 ES cells by the MD Anderson Cancer Center (MDACC) Genetically Engineered Mouse Facility. G 418 -resistant FIAUsensitive ES clones were examined for targeting by Southern blotting. Genomic DNA (20 mg) was digested with Hind III and blots were transferred onto Hybond N þ Nylon membrane (Amersham Pharmacia, Piscataway, NJ, USA). Both 5 0 and 3 0 probes were used to identify targeted clones. Chimeras were generated from two ES cell clones.
PCR primers
For Mtbp genotyping, we used the following primer pairs: CAAGGCGATTAAGTTGGGTAACGCCAG, CAGCAAG TACCGATCCATCCTCTTCG and GCACTAAATCCCTG TGAACACTGCTCTTC. For p53 genotyping, primers were previously described . The same primer sets were used for Mtbp and p53 LOH studies, and PCR was performed for 22 cycles.
Invasion and migration assays
For siRNA transfection, HiPerFect (Qiagen, Valenica, CA, USA) was used according to the manufacturer's recommendations. The Mtbp specific siRNA used was GGUUGGUGCUCUCUUU GUG. Control nontargeting siRNA#1 and Gfp-encoding adenoviral vector were purchased from Dharmacon (Chicago, IL, USA) and MP Biomedicals (Solon, OH, USA), respectively. Nterminal FLAG-tagged Mtbp-encoding adenovirus was generated in the Vector Core Laboratory at LSUHSC. Invasion assays were performed 24 h after transfection or infection. For invasion assays, Growth Factor-Reduced Matrigel Matrix (BD Biosciences, San Jose, CA, USA) was used for coating the upper compartment of Transwell chambers (6.5 mm diameter, 8 mm pore size; Corning, Corning, NY, USA). Fetal calf serum (0.3%) was used as a chemoattractant. Cells (1 Â 10 4 per 100 ml Dulbecco's modified Eagle's medium) were incubated for 16 h, and fixed and stained with Diff-Quik Stain Set (Dade Behring, Newark, DE, USA). Cells on the entire filter were counted. Migration assays were performed using Transwell without coating. MEFs (1 Â 10 4 per 100 ml) in 0.5% of FCS were added to upper compartment. FCS (10%) was used as a chemoattractant. Migrated cells were counted as described above. Experiments were performed in duplicate at least four times.
Quantitative RT-PCR by TaqMan assays RNeasy (Qiagen) and First-Strand cDNA Synthesis (Amersham Pharmacia) kits were used for RNA isolation and reverse transcriptase reactions, respectively. The Cell-to-cDNA kit (Ambion, Foster City, CA, USA) was used for RNA preparation from blastocysts. TaqMan assays were performed according to the manufacturer's specifications (Applied Biosystems, Foster City, CA, USA) using the following probes: Gapdh (Mm99999915_g1), Mtbp (Mm01195350_m1) and MrpL13 (Mm00452782_m1). Relative mRNA expression was normalized to the value of gapdh for each reaction.
Antibodies
Antibodies namely MTBP (sc-47173, Santa Cruz, Santa Cruz, CA, USA), Vinculin (RD1-CBL233, Fitzgerald, Concord, MA, USA), p53 (CM5, Novocastra, Norwell, MA, USA), b-actin (A5441, Sigma, St Louis, MA, USA) and Mdm2 (9321) (Reinke et al., 1999) were used.
